SCHEMBL5568547

SCHEMBL5568547

Cc1nc2c3c(c(CCl)cn2c1C)CCC(c1ccccc1)C3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.41
CYP2C9 P11712 6/20 0.41
HCAR2 Q8TDS4 1/20 0.33
SRD5A1 P18405 1/20 0.33
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
BRD4 O60885 1/20 0.32
GRM2 Q14416 2/20 0.32
ADRA1A P35348 2/20 0.31
ATP4A P20648 2/20 0.31
ATP4B P51164 2/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
CSF1R P07333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567838 0.89 CYP3A4 (0.41) CYP3A4CYP2C9HCAR2SRD5A1LMNA
SCHEMBL5567533 0.87 CYP3A4 (0.39) CYP3A4CYP2C9HCAR2SRD5A1LMNA
SCHEMBL5567826 0.83 CYP3A4 (0.42) CYP3A4CYP2C9HCAR2SRD5A1LMNA
SCHEMBL5564813 0.80 HCAR2 (0.43) CYP3A4CYP2C9HCAR2SRD5A1LMNA
SCHEMBL5567085 0.78 CYP3A4 (0.41) CYP3A4CYP2C9HCAR2SRD5A1LMNA
SCHEMBL5567092 0.77 CYP3A4 (0.39) CYP3A4CYP2C9HCAR2LMNAGAA
SCHEMBL5567457 0.77 CYP3A4 (0.40) CYP3A4CYP2C9HCAR2SRD5A1BRD4
SCHEMBL5564848 0.77 CYP3A4 (0.40) CYP3A4CYP2C9HCAR2SRD5A1GAA
SCHEMBL5567700 0.76 SPR (0.41) CYP3A4CYP2C9HCAR2LMNAPOLB
SCHEMBL5568619 0.74 ALDH1A1 (0.42) CYP3A4CYP2C9LMNAPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines ALTANA PHARMA AG (DE) 2007-08-30 US disclosed
EP-1805173-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2007-07-11 EP disclosed
WO-2005090346-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines GIPR, CCKBR, SLC10A2 CYP3A4 292/4885CYP2C9 112/4885HCAR2 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.